{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=44&state=California", "query": { "state": "California", "city": "Fullerton", "page": 44 }, "page_size": 10 }, "pagination": { "page": 44, "page_size": 10, "total_count": 1114, "total_pages": 112, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=45&state=California&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=43&state=California&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T15:15:47.118Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07106762", "title": "Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Urothelial Cancer" ], "interventions": [ { "name": "Iza-bren", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 470, "start_date": "2025-09-30", "completion_date": "2033-11-18", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-11-05T15:15:47.118Z", "location_count": 35, "location_summary": "Gilbert, Arizona • Fullerton, California • Palo Alto, California + 26 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07106762" }, { "nct_id": "NCT06158841", "title": "Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Etentamig", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 421, "start_date": "2024-05-19", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-11-05T15:15:47.118Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06158841" }, { "nct_id": "NCT01013077", "title": "The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dry Eye Syndrome" ], "interventions": [ { "name": "Optive, Soothe, New Emulsion", "type": "OTHER" }, { "name": "Soothe, New Emulsion, Optive", "type": "OTHER" }, { "name": "New Emulsion, Optive, Soothe", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Southern California College of Optometry at Marshall B. Ketchum University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2009-11", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2025-06-12", "last_synced_at": "2026-11-05T15:15:47.118Z", "location_count": 1, "location_summary": "Fullerton, California", "locations": [ { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01013077" }, { "nct_id": "NCT05799495", "title": "A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "SARS-CoV-2 Infection" ], "interventions": [ { "name": "PF-07817883", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 240, "start_date": "2023-05-23", "completion_date": "2023-10-11", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-11-05T15:15:47.118Z", "location_count": 53, "location_summary": "Cullman, Alabama • Phoenix, Arizona • Surprise, Arizona + 45 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Surprise", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05799495" }, { "nct_id": "NCT00312845", "title": "Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Bortezomib + Rituximab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 676, "start_date": "2006-03", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2012-06-25", "last_synced_at": "2026-11-05T15:15:47.118Z", "location_count": 41, "location_summary": "Opelika, Alabama • Alhambra, California • Bakersfield, California + 36 more", "locations": [ { "city": "Opelika", "state": "Alabama" }, { "city": "Alhambra", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00312845" }, { "nct_id": "NCT00891462", "title": "Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Aclidinium bromide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 561, "start_date": "2009-04", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2017-01-06", "last_synced_at": "2026-11-05T15:15:47.118Z", "location_count": 104, "location_summary": "Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00891462" }, { "nct_id": "NCT01202188", "title": "A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease (COPD)" ], "interventions": [ { "name": "indacaterol and glycopyrronium (QVA149)", "type": "DRUG" }, { "name": "glycopyrronium (NVA237)", "type": "DRUG" }, { "name": "indacaterol (QAB149)", "type": "DRUG" }, { "name": "tiotropium", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 2144, "start_date": "2010-09", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2013-09-09", "last_synced_at": "2026-11-05T15:15:47.118Z", "location_count": 14, "location_summary": "Fullerton, California • Riverside, California • St. Petersburg, Florida + 11 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Troy", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01202188" }, { "nct_id": "NCT04553770", "title": "Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Early-stage Breast Cancer", "Hormone Receptor Positive Breast Carcinoma", "Invasive Breast Cancer", "Stage II Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage III Breast Cancer" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2020-10-09", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-11-05T15:15:47.118Z", "location_count": 9, "location_summary": "Fullerton, California • Los Alamitos, California • Los Angeles, California + 6 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04553770" }, { "nct_id": "NCT01013142", "title": "Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "MN-221 (Dose Group 1)", "type": "DRUG" }, { "name": "MN-221 (Dose Group 2)", "type": "DRUG" }, { "name": "MN-221 (Dose Group 3)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MediciNova", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "40 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2009-11", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2015-05-13", "last_synced_at": "2026-11-05T15:15:47.118Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Fullerton, California • Tamarac, Florida + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Tamarac", "state": "Florida" }, { "city": "Winter Park", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01013142" }, { "nct_id": "NCT03375320", "title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Functioning Pancreatic Neuroendocrine Tumor", "Intermediate Grade Lung Neuroendocrine Neoplasm", "Locally Advanced Digestive System Neuroendocrine Neoplasm", "Locally Advanced Digestive System Neuroendocrine Tumor G1", "Locally Advanced Lung Neuroendocrine Neoplasm", "Locally Advanced Pancreatic Neuroendocrine Tumor", "Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm", "Low Grade Lung Neuroendocrine Neoplasm", "Lung Neuroendocrine Tumor", "Lung Neuroendocrine Tumor G2", "Metastatic Digestive System Neuroendocrine Neoplasm", "Metastatic Digestive System Neuroendocrine Tumor G1", "Metastatic Lung Neuroendocrine Neoplasm", "Metastatic Lung Neuroendocrine Tumor", "Metastatic Pancreatic Neuroendocrine Neoplasm", "Metastatic Pancreatic Neuroendocrine Tumor", "Metastatic Thymus Neuroendocrine Neoplasm", "Neuroendocrine Neoplasm", "Neuroendocrine Tumor", "Neuroendocrine Tumor G2", "Non-Functioning Pancreatic Neuroendocrine Tumor", "Pancreatic Serotonin-Producing Neuroendocrine Tumor", "Thymus Neuroendocrine Tumor", "Unresectable Digestive System Neuroendocrine Neoplasm", "Unresectable Digestive System Neuroendocrine Tumor G1", "Unresectable Lung Neuroendocrine Neoplasm", "Unresectable Pancreatic Neuroendocrine Neoplasm", "Unresectable Thymus Neuroendocrine Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 298, "start_date": "2018-10-26", "completion_date": "2027-09-01", "has_results": true, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-05T15:15:47.118Z", "location_count": 432, "location_summary": "Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 289 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03375320" } ] }